









Markets
/
Stocks
/
nasdaq-rxst
/

Rxsight Inc

RXST

9.490USD

+0.530+5.92%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

388.27MMarket Cap

LossP/E TTM



Rxsight Inc

9.490

+0.530+5.92%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

84 / 207

Overall Ranking

213 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Hold

Current Rating

9.000

Target Price

+0.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 185.54% year-on-year.

Overvalued

The company’s latest PE is -11.94, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.83M shares, decreasing 8.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.27M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.03, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 33.64M, representing a year-over-year decrease of 3.58%, while its net profit experienced a year-over-year decrease of 93.88%.

Score

Industry at a Glance

Previous score

7.03

Change



Financials

8.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.07

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.36

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -11.27, which is 8.07% below the recent high of -12.18 and -266.80% above the recent low of -41.35.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 84/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 5.82, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Rxsight Inc is 9.00, with a high of 11.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

5.82

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Hold

Current Rating

9.000

Target Price

+0.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Rxsight Inc

RXST

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.73, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 10.07 and the support level at 8.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.73

Change

0.4

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.060

Buy

RSI(14)

55.969

Neutral

STOCH(KDJ)(9,3,3)

45.868

Neutral

ATR(14)

0.536

High Vlolatility

CCI(14)

32.701

Neutral

Williams %R

38.776

Buy

TRIX(12,20)

0.513

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

9.214

Buy

MA10

9.312

Buy

MA20

9.052

Buy

MA50

8.304

Buy

MA100

11.300

Sell

MA200

20.247

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 100.45%, representing a quarter-over-quarter increase of 0.66%. The largest institutional shareholder is The Vanguard, holding a total of 2.27M shares, representing 5.55% of shares outstanding, with 5.56% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

3.74M

Millennium Management LLC

897.85K

-10.89%

BlackRock Institutional Trust Company, N.A.

2.56M

-0.72%

The Vanguard Group, Inc.

Star Investors

2.38M

+0.36%

Artisan Partners Limited Partnership

1.77M

+13.91%

DWS Investments UK Limited

654.76K

-0.26%

NO STREET GP LP

600.00K

+20.00%

Brown Capital Management, LLC

947.29K

+12.48%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 2.98, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.